Resources

News

January 31, 2022

Ablexis and AlivaMab Discovery Services Announce Agreements with Almirall to Accelerate Antibody Drug Discovery and Development

Ablexis’ multi-target licensing agreement grants Almirall rights to use the AlivaMab® Mouse technology for research, development and commercialization of antibodies ...
CONTINUE READING

January 11, 2022

AlivaMab Discovery Services Appoints Jane Seagal, PhD, as Vice President of Antibody Discovery

AbbVie veteran to support rapid growth and new technologies. SAN DIEGO, Calif. – January 11, 2022 – AlivaMab Discovery Services (“ADS”), a ...
CONTINUE READING

November 1, 2021

AlivaMab Discovery Services Expands Discovery Agreement with IGM Biosciences

Expanded agreement aims to accelerate the discovery of next-generation antibody modalities SAN DIEGO, Calif. – November 1, 2021 – AlivaMab Discovery ...
CONTINUE READING

September 14, 2021

AlivaMab Discovery Services Announces Multi-Target Agreement with Teva Pharmaceuticals

Agreement aims to accelerate the discovery of new therapeutics SAN DIEGO, Calif. – September 14, 2021 – AlivaMab Discovery Services (“ADS”), a ...
CONTINUE READING

May 12, 2021

AlivaMab Discovery Services Expands Drug Discovery Platform with the Launch of New Antibody Engineering Department

Jonah Rainey, Ph.D., joins ADS to bring new breadth and depth of capabilities and expertise in discovering therapeutic antibody modalities ...
CONTINUE READING

December 14, 2020

AlivaMab Discovery Services Expands Drug Discovery Platform into Developability Assessment

Expansion gives AlivaMab Discovery Services the ability to streamline the transition of drug discovery programs into development SAN DIEGO, Calif ...
CONTINUE READING

June 3, 2020

AlivaMab Discovery Services (ADS) Announces Agreement with Tanabe Research Laboratories USA

ADS announces integrated antibody drug discovery collaboration SAN DIEGO, Calif. – June 3, 2020 – AlivaMab Discovery Services, LLC, a ...
CONTINUE READING

May 20, 2020

AlivaMab Discovery Services Announces Planned Leadership Transition

Article Highlights Larry Green, PhD transitions from chief executive officer (CEO) to chairman, board of directors Justin Mika to succeed ...
CONTINUE READING

April 22, 2020

Ablexis, AlivaMab Discovery Services, and Berkeley Lights Collaborate to Identify a Diverse Panel of Anti-SARS-CoV-2 Human Antibodies

Offers unique resources for COVID-19 therapeutic discovery SAN DIEGO and EMERYVILLE, Calif. – April 22, 2020 – Ablexis, LLC, AlivaMab ...
CONTINUE READING

September 16, 2019

AlivaMab Discovery Services Announces Multi-Target Agreement with Janssen

ADS to provide expertise and capabilities in antibody drug discovery SAN DIEGO, Calif. – September 16, 2019 – AlivaMab Discovery ...
CONTINUE READING

February 26, 2019

AlivaMab Discovery Services Identifies Highly Potent Antibodies in Two Months for Inaugural Client Project

Company Expands Team with Veterans of Antibody Discovery and Development SAN DIEGO, Calif. – February 26, 2019 – AlivaMab ...
CONTINUE READING

Case Studies

From Novel Assay Development to Quality Therapeutic Leads on a Rapid Timeline

Webinars & Presentations

Engineering Human Antibodies Discovered with AlivaMab^® Mouse into a Dual-Antagonist Bispecific Antibody Therapeutic

Biologics UK 2022

WATCH

Features & Interviews

Profile from Nature’s BioPharma Dealmakers September 2021

Ablexis and AlivaMab Discovery Services. Unparalleled success in antibody discovery and development.

DOWNLOAD

Pharmaceutical Executive speaks with Larry Green

From Mouse to Mab

READ

Nature speaks to Larry Green, Founder and Executive Chairman

Harnessing platform technology and expertise to fuel antibody drug discovery

DOWNLOAD

Resources

News

Ablexis and AlivaMab Discovery Services Announce Agreements with Almirall to Accelerate Antibody Drug Discovery and Development

AlivaMab Discovery Services Appoints Jane Seagal, PhD, as Vice President of Antibody Discovery

AlivaMab Discovery Services Expands Discovery Agreement with IGM Biosciences

AlivaMab Discovery Services Announces Multi-Target Agreement with Teva Pharmaceuticals

AlivaMab Discovery Services Expands Drug Discovery Platform with the Launch of New Antibody Engineering Department

AlivaMab Discovery Services Expands Drug Discovery Platform into Developability Assessment

AlivaMab Discovery Services (ADS) Announces Agreement with Tanabe Research Laboratories USA

AlivaMab Discovery Services Announces Planned Leadership Transition

Ablexis, AlivaMab Discovery Services, and Berkeley Lights Collaborate to Identify a Diverse Panel of Anti-SARS-CoV-2 Human Antibodies

AlivaMab Discovery Services Announces Multi-Target Agreement with Janssen

AlivaMab Discovery Services Identifies Highly Potent Antibodies in Two Months for Inaugural Client Project

Case Studies

From Novel Assay Development to Quality Therapeutic Leads on a Rapid Timeline

Breaking Immune Tolerance to Generate Highly Potent Cross-Reactive Antibodies

Generating Diverse Antibodies Against Multi-Spanning Membrane Protein Targets

Webinars & Presentations

Engineering Human Antibodies Discovered with AlivaMab^® Mouse into a Dual-Antagonist Bispecific Antibody Therapeutic

Upcoming Events

World Multispecifics Summit

West Coast Antibody Therapeutics Xchange

Festival of Biologics Basel

PEGS Europe

Antibody Engineering & Therapeutics

Features & Interviews

Profile from Nature’s BioPharma Dealmakers September 2021

Pharmaceutical Executive speaks with Larry Green

Nature speaks to Larry Green, Founder and Executive Chairman

Let’s Make Better Medicines Together

Resources

News

Case Studies

Webinars & Presentations

Engineering Human Antibodies Discovered with AlivaMab® Mouse into a Dual-Antagonist Bispecific Antibody Therapeutic

Upcoming Events

World Multispecifics Summit

West Coast Antibody Therapeutics Xchange

Festival of Biologics Basel

PEGS Europe

Antibody Engineering & Therapeutics

Features & Interviews

Profile from Nature’s BioPharma Dealmakers September 2021

Pharmaceutical Executive speaks with Larry Green

Nature speaks to Larry Green, Founder and Executive Chairman

Let’s Make Better Medicines Together

Engineering Human Antibodies Discovered with AlivaMab^® Mouse into a Dual-Antagonist Bispecific Antibody Therapeutic